2 terminated, 1 completed, 1 recruiting, 1 withdrawn. 5 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Terminated 2, Completed 1, Recruiting 1, Withdrawn 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow SLL: new trials by email Literature Review of SLL trials Research Report on SLL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia CAP-100 - Lymphocytic Leukemia, Chronic, SLL | Phase 1 | Recruiting | Catapult Therapeutics | 18 | 2021-09-10 | 2025-07-17 |
| Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia TG-1801, Ublituximab - CLL, SLL | Phase 1 | Terminated | TG Therapeutics, Inc. | 21 | 2021-04-28 | 2024-07-31 |
| Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL Dose combination 1-1, dose combination 1-2, Dose combination 1-3 - Chronic Lymphocytic Leukemia, CLL | Phase 1 | Withdrawn | Virginia Commonwealth University | 2020-10-02 | 2021-11-09 | |
| Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL TP-0903, TP-0903 and ibrutinib combination therapy - Chronic Lymphocytic Leukemia, CLL | Phase 1 / Phase 2 | Terminated | Sumitomo Pharma America, Inc. | 3 | 2019-06-10 | 2023-11-09 |
| Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL veltuzumab - NHL, Lymphoma, Non-Hodgkin | Phase 1 / Phase 2 | Completed | Gilead Sciences | 32 | 2008-01-01 | 2021-08-16 |
Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma, Follicular (2) · Dendritic Cell Sarcoma, Interdigitating (1) · Leukemia (1) · Leukemia, Prolymphocytic (1) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Non-Hodgkin (1) · Neoplasms (1) · Recurrence (1)
Hemic and Lymphatic Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Lymphatic Diseases (5) · Lymphoproliferative Disorders (5) · Neoplasms by Histologic Type (5) · Chronic Disease (4) · Disease Attributes (4) · Hematologic Diseases (4) · Leukemia, B-Cell (4) · Leukemia, Lymphoid (4) · Neoplasms (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Leukemia (3)
LFB-R603 (1) · dubermatinib (1) · ublituximab (1) · veltuzumab (1)
Catapult Therapeutics (1) · Gilead Sciences (1) · Sumitomo Pharma America, Inc. (1) · TG Therapeutics, Inc. (1) · Virginia Commonwealth University (1)
United States (4) · Spain (1)
Phillip Komarnitsky (1) · Victor Y Yazbek, MD, MS (1) · William Wegener, MD, PhD (1)